VANDA PHARMACEUTICALS INC. Payments to Acquire Debt Securities, Available-for-sale
VANDA PHARMACEUTICALS INC. (VNDA) reported Payments to Acquire Debt Securities, Available-for-sale of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2026-08-06
- VANDA PHARMACEUTICALS INC. payments to acquire debt securities, available-for-sale for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- VANDA PHARMACEUTICALS INC. payments to acquire debt securities, available-for-sale for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- VANDA PHARMACEUTICALS INC. payments to acquire debt securities, available-for-sale for the quarter ending 2025-12-31 was $2.03M, a 97.80% decline year-over-year.
- VANDA PHARMACEUTICALS INC. payments to acquire debt securities, available-for-sale for the quarter ending 2025-09-30 was $14.05M, a 83.22% decline year-over-year.
- VANDA PHARMACEUTICALS INC. payments to acquire debt securities, available-for-sale for fiscal 2025 was $112.38M, a 69.19% decline from fiscal 2024.
- VANDA PHARMACEUTICALS INC. payments to acquire debt securities, available-for-sale for fiscal 2024 was $364.77M, a 28.84% decline from fiscal 2023.
- VANDA PHARMACEUTICALS INC. payments to acquire debt securities, available-for-sale for fiscal 2023 was $512.61M, a 46.77% increase from fiscal 2022.
- VANDA PHARMACEUTICALS INC. payments to acquire debt securities, available-for-sale for fiscal 2022 was $349.26M, a 16.93% decline from fiscal 2021.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 3 month | Payments to Acquire Debt Securities, Available-for-sale 6 month | Payments to Acquire Debt Securities, Available-for-sale 9 month | Payments to Acquire Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $0.00 10-Q · filed 2026-08-06 | $2.03M derived: sum of 3 quarters · filed 2026-08-06 | $16.08M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-07 | $2.03M derived: sum of 2 quarters · filed 2026-05-07 | $16.08M derived: sum of 3 quarters · filed 2026-05-07 | $69.05M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $2.03M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $16.08M derived: sum of 2 quarters · filed 2026-02-12 | $69.05M derived: sum of 3 quarters · filed 2026-08-06 | $112.38M 10-K · filed 2026-02-12 |
| 2025-09-30 | $14.05M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $67.02M derived: sum of 2 quarters · filed 2026-08-06 | $110.35M 10-Q · filed 2025-10-30 | $202.75M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $52.97M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $96.30M 10-Q · filed 2026-08-06 | $188.70M derived: sum of 3 quarters · filed 2026-08-06 | $272.44M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $43.33M 10-Q · filed 2026-05-07 | $135.73M derived: sum of 2 quarters · filed 2026-05-07 | $219.47M derived: sum of 3 quarters · filed 2026-05-07 | $332.10M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $92.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $176.14M derived: sum of 2 quarters · filed 2026-02-12 | $288.77M derived: sum of 3 quarters · filed 2026-02-12 | $364.77M 10-K · filed 2026-02-12 |
| 2024-09-30 | $83.73M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $196.36M derived: sum of 2 quarters · filed 2025-10-30 | $272.37M 10-Q · filed 2025-10-30 | $327.35M derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-06-30 | $112.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-31 | $188.64M 10-Q · filed 2025-07-31 | $243.61M derived: sum of 3 quarters · filed 2026-02-12 | $290.26M derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-03-31 | $76.01M 10-Q · filed 2025-05-08 | $130.98M derived: sum of 2 quarters · filed 2026-02-12 | $177.63M derived: sum of 3 quarters · filed 2026-02-12 | $425.57M derived: sum of 4 quarters · filed 2026-02-12 |
| 2023-12-31 | $54.98M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $101.63M derived: sum of 2 quarters · filed 2026-02-12 | $349.56M derived: sum of 3 quarters · filed 2026-02-12 | $512.61M 10-K · filed 2026-02-12 |
| 2023-09-30 | $46.65M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $294.58M derived: sum of 2 quarters · filed 2024-11-07 | $457.63M 10-Q · filed 2024-11-07 | $461.94M derived: sum of 4 quarters · filed 2025-02-14 |
| 2023-06-30 | $247.93M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $410.98M 10-Q · filed 2024-08-01 | $415.29M derived: sum of 3 quarters · filed 2025-02-14 | $584.25M derived: sum of 4 quarters · filed 2025-02-14 |
| 2023-03-31 | $163.04M 10-Q · filed 2024-05-09 | $167.35M derived: sum of 2 quarters · filed 2025-02-14 | $336.32M derived: sum of 3 quarters · filed 2025-02-14 | $433.17M derived: sum of 4 quarters · filed 2025-02-14 |
| 2022-12-31 | $4.31M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-14 | $173.27M derived: sum of 2 quarters · filed 2025-02-14 | $270.12M derived: sum of 3 quarters · filed 2025-02-14 | $349.26M 10-K · filed 2025-02-14 |
| 2022-09-30 | $168.96M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $265.81M derived: sum of 2 quarters · filed 2023-11-09 | $344.95M 10-Q · filed 2023-11-09 | $450.22M derived: sum of 4 quarters · filed 2024-02-08 |
| 2022-06-30 | $96.85M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-07-28 | $175.99M 10-Q · filed 2023-07-28 | $281.26M derived: sum of 3 quarters · filed 2024-02-08 | $399.09M derived: sum of 4 quarters · filed 2024-02-08 |
| 2022-03-31 | $79.13M 10-Q · filed 2023-05-03 | $184.41M derived: sum of 2 quarters · filed 2024-02-08 | $302.24M derived: sum of 3 quarters · filed 2024-02-08 | $406.54M derived: sum of 4 quarters · filed 2024-02-08 |
| 2021-12-31 | $105.27M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-08 | $223.11M derived: sum of 2 quarters · filed 2024-02-08 | $327.40M derived: sum of 3 quarters · filed 2024-02-08 | $420.46M 10-K · filed 2024-02-08 |
| 2021-09-30 | $117.83M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $222.13M derived: sum of 2 quarters · filed 2022-11-03 | $315.19M 10-Q · filed 2022-11-03 | $397.70M derived: sum of 4 quarters · filed 2023-02-09 |
| 2021-06-30 | $104.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $197.35M 10-Q · filed 2022-08-04 | $279.86M derived: sum of 3 quarters · filed 2023-02-09 | $392.85M derived: sum of 4 quarters · filed 2023-02-09 |
| 2021-03-31 | $93.06M 10-Q · filed 2022-05-06 | $175.57M derived: sum of 2 quarters · filed 2023-02-09 | $288.56M derived: sum of 3 quarters · filed 2023-02-09 | $398.28M derived: sum of 4 quarters · filed 2023-02-09 |
| 2020-12-31 | $82.51M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-09 | $195.50M derived: sum of 2 quarters · filed 2023-02-09 | $305.22M derived: sum of 3 quarters · filed 2023-02-09 | $346.62M 10-K · filed 2023-02-09 |
| 2020-09-30 | $112.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $222.71M derived: sum of 2 quarters · filed 2021-11-04 | $264.11M 10-Q · filed 2021-11-04 | $367.30M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | $109.72M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-29 | $151.12M 10-Q · filed 2021-07-29 | $254.31M derived: sum of 3 quarters · filed 2022-02-24 | $354.35M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-03-31 | $41.40M 10-Q · filed 2021-05-06 | $144.58M derived: sum of 2 quarters · filed 2022-02-24 | $244.62M derived: sum of 3 quarters · filed 2022-02-24 | $335.11M derived: sum of 4 quarters · filed 2022-02-24 |
| 2019-12-31 | $103.18M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $203.22M derived: sum of 2 quarters · filed 2022-02-24 | $293.71M derived: sum of 3 quarters · filed 2022-02-24 | $394.52M 10-K · filed 2022-02-24 |
| 2019-09-30 | $100.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-29 | $190.53M derived: sum of 2 quarters · filed 2020-10-29 | $291.33M 10-Q · filed 2020-10-29 | $371.79M derived: sum of 4 quarters · filed 2021-02-11 |
| 2019-06-30 | $90.49M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $191.29M 10-Q · filed 2020-08-06 | $271.75M derived: sum of 3 quarters · filed 2021-02-11 | $343.15M derived: sum of 4 quarters · filed 2021-02-11 |
| 2019-03-31 | $100.80M 10-Q · filed 2020-05-07 | $181.26M derived: sum of 2 quarters · filed 2021-02-11 | $252.66M derived: sum of 3 quarters · filed 2021-02-11 | $352.76M derived: sum of 4 quarters · filed 2021-02-11 |
| 2018-12-31 | $80.45M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-11 | $151.86M derived: sum of 2 quarters · filed 2021-02-11 | $251.96M derived: sum of 3 quarters · filed 2021-02-11 | $282.39M 10-K · filed 2021-02-11 |
| 2018-09-30 | $71.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $171.51M derived: sum of 2 quarters · filed 2019-11-07 | $201.94M 10-Q · filed 2019-11-07 | $240.68M derived: sum of 4 quarters · filed 2020-02-26 |
| 2018-06-30 | $100.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-01 | $130.54M 10-Q · filed 2019-08-01 | $169.28M derived: sum of 3 quarters · filed 2020-02-26 | $197.50M derived: sum of 4 quarters · filed 2020-02-26 |
| 2018-03-31 | $30.43M 10-Q · filed 2019-05-03 | $69.17M derived: sum of 2 quarters · filed 2020-02-26 | $97.40M derived: sum of 3 quarters · filed 2020-02-26 | $125.10M derived: sum of 4 quarters · filed 2020-02-26 |
| 2017-12-31 | $38.74M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-26 | $66.96M derived: sum of 2 quarters · filed 2020-02-26 | $94.67M derived: sum of 3 quarters · filed 2020-02-26 | $148.13M 10-K · filed 2020-02-26 |
| 2017-09-30 | $28.23M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | $55.93M derived: sum of 2 quarters · filed 2018-11-07 | $109.40M 10-Q · filed 2018-11-07 | $143.94M derived: sum of 4 quarters · filed 2019-02-19 |
| 2017-06-30 | $27.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-02 | $81.17M 10-Q · filed 2018-08-02 | $115.72M derived: sum of 3 quarters · filed 2019-02-19 | $142.58M derived: sum of 4 quarters · filed 2019-02-19 |
| 2017-03-31 | $53.47M 10-Q · filed 2018-05-02 | $88.01M derived: sum of 2 quarters · filed 2019-02-19 | $114.88M derived: sum of 3 quarters · filed 2019-02-19 | $171.56M derived: sum of 4 quarters · filed 2019-02-19 |
| 2016-12-31 | $34.55M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-19 | $61.41M derived: sum of 2 quarters · filed 2019-02-19 | $118.09M derived: sum of 3 quarters · filed 2019-02-19 | $165.41M 10-K · filed 2019-02-19 |
| 2016-09-30 | $26.86M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $83.55M derived: sum of 2 quarters · filed 2017-11-08 | $130.86M 10-Q · filed 2017-11-08 | $196.36M derived: sum of 4 quarters · filed 2018-02-15 |
| 2016-06-30 | $56.68M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | $103.99M 10-Q · filed 2017-08-03 | $169.50M derived: sum of 3 quarters · filed 2018-02-15 | $215.76M derived: sum of 4 quarters · filed 2018-02-15 |
| 2016-03-31 | $47.31M 10-Q · filed 2017-05-03 | $112.81M derived: sum of 2 quarters · filed 2018-02-15 | $159.07M derived: sum of 3 quarters · filed 2018-02-15 | $180.53M derived: sum of 4 quarters · filed 2018-02-15 |
| 2015-12-31 | $65.50M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-15 | $111.76M derived: sum of 2 quarters · filed 2018-02-15 | $133.22M derived: sum of 3 quarters · filed 2018-02-15 | $193.11M 10-K · filed 2018-02-15 |
| 2015-09-30 | $46.26M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | $67.72M derived: sum of 2 quarters · filed 2016-11-03 | $127.61M 10-Q · filed 2016-11-03 | $180.57M derived: sum of 4 quarters · filed 2017-02-17 |
| 2015-06-30 | $21.46M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-07-28 | $81.35M 10-Q · filed 2016-07-28 | $134.31M derived: sum of 3 quarters · filed 2017-02-17 | $154.15M derived: sum of 4 quarters · filed 2017-02-17 |
| 2015-03-31 | $59.89M 10-Q · filed 2016-05-05 | $112.85M derived: sum of 2 quarters · filed 2017-02-17 | $132.69M derived: sum of 3 quarters · filed 2017-02-17 | $150.91M derived: sum of 4 quarters · filed 2017-02-17 |
| 2014-12-31 | $52.96M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-17 | $72.80M derived: sum of 2 quarters · filed 2017-02-17 | $91.02M derived: sum of 3 quarters · filed 2017-02-17 | $93.34M 10-K · filed 2017-02-17 |
| 2014-09-30 | $19.84M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-04 | $38.06M derived: sum of 2 quarters · filed 2015-11-04 | $40.38M 10-Q · filed 2015-11-04 | |
| 2014-06-30 | $18.23M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-07-31 | $20.54M 10-Q · filed 2015-07-31 | ||
| 2014-03-31 | $2.32M 10-Q · filed 2015-05-07 | |||
| 2013-12-31 | $65.60M 10-K · filed 2016-02-12 | |||
| 2012-12-31 | $10.90M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-13 | $10.90M derived: sum of 2 quarters · filed 2015-03-13 | $31.67M derived: sum of 3 quarters · filed 2015-03-13 | $60.87M 10-K · filed 2015-03-13 |
| 2012-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-08 | $20.77M derived: sum of 2 quarters · filed 2013-11-08 | $49.97M 10-Q · filed 2013-11-08 | $69.54M derived: sum of 4 quarters · filed 2014-02-25 |
| 2012-06-30 | $20.77M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-07-31 | $49.97M 10-Q · filed 2013-07-31 | $69.54M derived: sum of 3 quarters · filed 2014-02-25 | $120.60M derived: sum of 4 quarters · filed 2014-02-25 |
| 2012-03-31 | $29.19M 10-Q · filed 2013-05-10 | $48.77M derived: sum of 2 quarters · filed 2014-02-25 | $99.83M derived: sum of 3 quarters · filed 2014-02-25 | $142.01M derived: sum of 4 quarters · filed 2014-02-25 |
| 2011-12-31 | $19.58M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-25 | $70.64M derived: sum of 2 quarters · filed 2014-02-25 | $112.81M derived: sum of 3 quarters · filed 2014-02-25 | $160.21M 10-K · filed 2014-02-25 |
| 2011-09-30 | $51.06M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-08 | $93.24M derived: sum of 2 quarters · filed 2012-11-08 | $140.64M 10-Q · filed 2012-11-08 | $219.05M derived: sum of 4 quarters · filed 2013-02-26 |
| 2011-06-30 | $42.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-03 | $89.58M 10-Q · filed 2012-08-03 | $167.99M derived: sum of 3 quarters · filed 2013-02-26 | $228.14M derived: sum of 4 quarters · filed 2013-02-26 |
| 2011-03-31 | $47.40M 10-Q · filed 2012-05-09 | $125.81M derived: sum of 2 quarters · filed 2013-02-26 | $185.96M derived: sum of 3 quarters · filed 2013-02-26 | |
| 2010-12-31 | $78.41M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-26 | $138.56M derived: sum of 2 quarters · filed 2013-02-26 | $202.44M 10-K · filed 2013-02-26 | |
| 2010-09-30 | $60.15M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-07 | $124.03M 10-Q · filed 2011-11-07 | ||
| 2010-06-30 | $63.88M 10-Q · filed 2011-08-05 | |||
| 2009-12-31 | $11.37M 10-K · filed 2012-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |